{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"90.6","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"CBR: participants with complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR) and no resposne for at least 16 weeks. For hematologic tumors (acute myeloid leukemia); CR: as bone marrow- \\< 5% blasts, no blasts with auer rods, peripheral blood- neutrophils ≥1.0\\*10\\^9/L and/or platelets ≥100\\*10\\^9/L, ≤1% blasts, no evidence of extramedullary disease (such as CNS or soft tissue involvement), transfusion independent; CRi: all the CR criteria were involved but platelet and neutrophil transfusions were also allowed; PR: bone marrow- 50% or greater decrease (absolute range 5-25% blasts), \\< 5% of blasts contain auer rods, peripheral blood- neutrophils \\<1.0\\*10\\^9/L and/or platelets \\<100\\*10\\^9/L, no evidence of extramedullary disease; no response: in case a patient did not achieve CR, CRi, PR or relapse for an individual response assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an oral dose of 45 mg of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.","id":"OG000","title":"Binimetinib (MEK162)"}],"paramType":"NUMBER","populationDescription":"Full analysis set included all the participants who had received at least 1 dose of study drug. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 16","title":"CBR for Hematologic Tumors at Week 16: Acute Myeloid Leukemia","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}